{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:02:00Z","timestamp":1794243720100,"version":"4.9.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>Systemic anticancer therapies (SACTs) are the leading cause of drug-induced interstitial lung disease (ILD). As more novel SACTs become approved, the incidence of this potentially life-threatening adverse event (AE) may increase. Early detection of SACT-related ILD allows for prompt implementation of drug-specific management recommendations, improving the likelihood of AE resolution and, in some instances, widening the patient\u2019s eligibility for future cancer treatment options. ILD requires a diagnosis of exclusion through collaboration with the patient\u2019s multidisciplinary team to rule out other possible etiologies of new or worsening respiratory signs and symptoms. At Grade 1, ILD is asymptomatic, and thus the radiologist is key to detecting the AE prior to the disease severity worsening. Planned computed tomography scans should be reviewed for the presence of ILD in addition to being assessed for tumor response to treatment, and when ILD is suspected, a high-resolution computed tomography (HRCT) scan should be requested immediately. An HRCT scan, with &lt;\u20092-mm slice thickness, is the most appropriate method for detecting ILD. Multiple patterns of ILD exist, which can impact patient prognosis. The four main patterns include acute interstitial pneumonia \/ acute respiratory distress syndrome, organizing pneumonia, hypersensitivity pneumonitis, and non-specific interstitial pneumonia; their distinct radiological features, along with rarer patterns, are discussed here. Furthermore, HRCT is essential for following the course of ILD and might help to determine the intensity of AE management and the appropriateness of re-challenging with SACT, where indicated by drug-specific prescribing information. ILD events should be monitored closely until complete resolution.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Critical relevance statement<\/jats:title>\n                <jats:p>The incidence of potentially treatment-limiting and life-threatening systemic anticancer therapy-related interstitial lung disease (SACT-related ILD) events is likely increasing as more novel regimens become approved. This review provides best-practice recommendations for the early detection of SACT-related ILD by radiologists.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key Points<\/jats:title>\n                <jats:p><jats:list list-type=\"bullet\">\n                  <jats:list-item>\n                    <jats:p>Radiologists are crucial in detecting asymptomatic (Grade 1) ILD before severity\/prognosis worsens.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>High-resolution computed tomography is the most appropriate method for detecting ILD.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>Drug-induced ILD is a diagnosis of exclusion, involving a multidisciplinary team.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>Familiarity with common HRCT patterns, described here, is key for prompt detection.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>Physicians should highlight systemic anticancer therapies (SACTs) with a known risk for interstitial lung diseases (ILD) on scan requisitions.<\/jats:p>\n                  <\/jats:list-item>\n                <\/jats:list><\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13244-024-01771-z","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T16:02:20Z","timestamp":1722528140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The radiologist\u2019s role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-6084","authenticated-orcid":false,"given":"Julien","family":"Dinkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Kneidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"1771_CR1","unstructured":"Antoine MH, Mlika M (2023) Interstitial lung disease. In: StatPearls. StatPearls Publishing, Treasure Island, FL, USA"},{"key":"1771_CR2","unstructured":"Schraufnagel DE (2010) Breathing in America: diseases, progress, and hope, 1st Edn. American Thoracic Society, New York, NY, USA"},{"key":"1771_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/123876","volume":"2015","author":"M Kreuter","year":"2015","unstructured":"Kreuter M, Herth FJ, Wacker M et al (2015) Exploring clinical and epidemiological characteristics of interstitial lung diseases: rationale, aims, and design of a nationwide prospective registry\u2014the EXCITING-ILD registry. Biomed Res Int 2015:123876. https:\/\/doi.org\/10.1155\/2015\/123876","journal-title":"Biomed Res Int"},{"key":"1771_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.751181","volume":"8","author":"B Kaul","year":"2021","unstructured":"Kaul B, Cottin V, Collard HR, Valenzuela C (2021) Variability in global prevalence of interstitial lung disease. Front Med Lausanne 8:751181. https:\/\/doi.org\/10.3389\/fmed.2021.751181","journal-title":"Front Med Lausanne"},{"key":"1771_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2213-0802-2-4","volume":"2","author":"KC Meyer","year":"2014","unstructured":"Meyer KC (2014) Diagnosis and management of interstitial lung disease. Transl Respir Med 2:4. https:\/\/doi.org\/10.1186\/2213-0802-2-4","journal-title":"Transl Respir Med"},{"key":"1771_CR6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","volume":"7","author":"S Skeoch","year":"2018","unstructured":"Skeoch S, Weatherley N, Swift AJ et al (2018) Drug-induced interstitial lung disease: a systematic review. J Clin Med 7:356. https:\/\/doi.org\/10.3390\/jcm7100356","journal-title":"J Clin Med"},{"key":"1771_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100404","volume":"7","author":"P Conte","year":"2022","unstructured":"Conte P, Ascierto PA, Patelli G et al (2022) Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open 7:100404. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100404","journal-title":"ESMO Open"},{"key":"1771_CR8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1148\/radiol.2021203427","volume":"298","author":"T Johkoh","year":"2021","unstructured":"Johkoh T, Lee KS, Nishino M et al (2021) Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Radiology 298:550\u2013566. https:\/\/doi.org\/10.1148\/radiol.2021203427","journal-title":"Radiology"},{"key":"1771_CR9","unstructured":"U.S. Department of Health and Human Services (HSS) (2017) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 17 Jul 2023"},{"key":"1771_CR10","doi-asserted-by":"publisher","first-page":"e000815","DOI":"10.1136\/bmjresp-2020-000815","volume":"8","author":"O Moran-Mendoza","year":"2021","unstructured":"Moran-Mendoza O, Ritchie T, Aldhaheri S (2021) Fine crackles on chest auscultation in the early diagnosis of idiopathic pulmonary fibrosis: a prospective cohort study. BMJ Open Respir Res 8:e000815. https:\/\/doi.org\/10.1136\/bmjresp-2020-000815","journal-title":"BMJ Open Respir Res"},{"key":"1771_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/oncolo\/oyac107","volume":"27","author":"A Bardia","year":"2022","unstructured":"Bardia A, Harnden K, Mauro L et al (2022) Clinical practices and institutional protocols on prophylaxis, monitoring, and management of selected adverse events associated with trastuzumab deruxtecan. Oncologist 27:637\u2013645. https:\/\/doi.org\/10.1093\/oncolo\/oyac107","journal-title":"Oncologist"},{"key":"1771_CR12","unstructured":"U.S. Food & Drug Administration (FDA) (2024) KEYTRUDA (pembrolizumab): highlights of prescribing information (PI). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125514s124lbl.pdf. Accessed 15 Feb 2024"},{"key":"1771_CR13","unstructured":"U.S. Food and Drug Administration (FDA) (2024) ENHERTU (fam-trastuzumab deruxtecan-nxki): highlights of prescribing information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761139s028lbl.pdf. Accessed 19 Apr 2024"},{"key":"1771_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100553","volume":"7","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bianchini G, Cortes J et al (2022) Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open 7:100553. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100553","journal-title":"ESMO Open"},{"key":"1771_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102378","volume":"106","author":"SM Swain","year":"2022","unstructured":"Swain SM, Nishino M, Lancaster LH et al (2022) Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis \u2013 focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 106:102378. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102378","journal-title":"Cancer Treat Rev"},{"key":"1771_CR16","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","volume":"7","author":"P Tarantino","year":"2021","unstructured":"Tarantino P, Modi S, Tolaney SM et al (2021) Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol 7:1873\u20131881. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3595","journal-title":"JAMA Oncol"},{"key":"1771_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","volume":"51","author":"K Kubo","year":"2013","unstructured":"Kubo K, Azuma A, Kanazawa M et al (2013) Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 51:260\u2013277. https:\/\/doi.org\/10.1016\/j.resinv.2013.09.001","journal-title":"Respir Investig"},{"key":"1771_CR18","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/cas.13087","volume":"107","author":"K Yonemori","year":"2016","unstructured":"Yonemori K, Hirakawa A, Kawachi A et al (2016) Drug induced interstitial lung disease in oncology phase I trials. Cancer Sci 107:1830\u20131836. https:\/\/doi.org\/10.1111\/cas.13087","journal-title":"Cancer Sci"},{"key":"1771_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1465-9921-13-39","volume":"13","author":"O Matsuno","year":"2012","unstructured":"Matsuno O (2012) Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 13:39. https:\/\/doi.org\/10.1186\/1465-9921-13-39","journal-title":"Respir Res"},{"key":"1771_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874306401206010063","volume":"6","author":"M Schwaiblmair","year":"2012","unstructured":"Schwaiblmair M, Behr W, Haeckel T et al (2012) Drug induced interstitial lung disease. Open Respir Med J 6:63\u201374. https:\/\/doi.org\/10.2174\/1874306401206010063","journal-title":"Open Respir Med J"},{"key":"1771_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12950-023-00329-y","volume":"20","author":"S Yan","year":"2023","unstructured":"Yan S, Li M, Liu B et al (2023) Neutrophil extracellular traps and pulmonary fibrosis: an update. J Inflamm (Lond) 20:2. https:\/\/doi.org\/10.1186\/s12950-023-00329-y","journal-title":"J Inflamm (Lond)"},{"key":"1771_CR22","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1111\/cas.14686","volume":"111","author":"K Kumagai","year":"2020","unstructured":"Kumagai K, Aida T, Tsuchiya Y et al (2020) Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci 111:4636\u20134645. https:\/\/doi.org\/10.1111\/cas.14686","journal-title":"Cancer Sci"},{"key":"1771_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2016.02.008","volume":"40","author":"BE de Goeij","year":"2016","unstructured":"de Goeij BE, Lambert JM (2016) New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol 40:14\u201323. https:\/\/doi.org\/10.1016\/j.coi.2016.02.008","journal-title":"Curr Opin Immunol"},{"key":"1771_CR24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","volume":"20","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM (2023) Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol 20:558\u2013576. https:\/\/doi.org\/10.1038\/s41571-023-00783-w","journal-title":"Nat Rev Clin Oncol"},{"key":"1771_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/biology12010123","volume":"12","author":"E Sakamoto","year":"2023","unstructured":"Sakamoto E, Katahira Y, Mizoguchi I et al (2023) Chemical- and drug-induced allergic, inflammatory, and autoimmune diseases via haptenation. Biol Basel 12:123. https:\/\/doi.org\/10.3390\/biology12010123","journal-title":"Biol Basel"},{"key":"1771_CR26","unstructured":"U.S. Food & Drug Administration (FDA) (2017) ONIVYDE (irinotecan liposome injection): highlights of prescribing information (PI). https:\/\/www.ipsen.com\/websites\/Ipsen_Online\/wp-content\/uploads\/sites\/9\/2019\/01\/21083350\/ONIVYDE_USPI.pdf. Accessed 26 Jul 2023"},{"key":"1771_CR27","unstructured":"U.S. Food & Drug Administration (FDA) (2022) TYKERB (lapatinib): highlights of prescribing information (PI). https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/tykerb.pdf. Accessed 24 Jul 2023"},{"key":"1771_CR28","unstructured":"European Medicines Agency (EMA) AFINITOR: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/afinitor-epar-product-information_en.pdf. Accessed 25 Aug 2023"},{"key":"1771_CR29","unstructured":"European Medicines Agency (EMA) VERZENIOS: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/verzenios-epar-product-information_en.pdf. Accessed 25 Aug 2023"},{"key":"1771_CR30","unstructured":"European Medicines Agency (EMA) (2023) KADCYLA: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kadcyla-epar-product-information_en.pdf. Accessed 25 Aug 2023"},{"key":"1771_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","volume":"10","author":"Q Su","year":"2019","unstructured":"Su Q, Zhu EC, Wu J-B et al (2019) Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis. Front Immunol 10:108. https:\/\/doi.org\/10.3389\/fimmu.2019.00108","journal-title":"Front Immunol"},{"key":"1771_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.breast.2022.02.011","volume":"62","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Ma Z, Sun X et al (2022) Interstitial lung disease in patients treated with cyclin-dependent kinase 4\/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Breast 62:162\u2013169. https:\/\/doi.org\/10.1016\/j.breast.2022.02.011","journal-title":"Breast"},{"key":"1771_CR33","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1080\/17512433.2022.2121705","volume":"15","author":"Z Ma","year":"2022","unstructured":"Ma Z, Zhang Y, Zhu M et al (2022) Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO\u2019s pharmacovigilance database. Expert Rev Clin Pharmacol 15:1351\u20131361. https:\/\/doi.org\/10.1080\/17512433.2022.2121705","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1771_CR34","unstructured":"ClinicalTrials.gov (2016) NCT00829166. A study of trastuzumab emtansine versus capecitabine + lapatinib in participants with HER2-positive locally advanced or metastatic breast cancer (EMILIA). Updated. https:\/\/clinicaltrials.gov\/study\/NCT00829166. Accessed 2 Oct 2023"},{"key":"1771_CR35","unstructured":"ClinicalTrials.gov (2024) NCT01772472. A study of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE). Updated. https:\/\/clinicaltrials.gov\/study\/NCT01772472. Accessed 2 Oct 2023"},{"key":"1771_CR36","unstructured":"ClinicalTrials.gov (2017) NCT01641939. A study of trastuzumab emtansine versus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. Updated. https:\/\/clinicaltrials.gov\/study\/NCT01641939. Accessed 2 Oct 2023"},{"key":"1771_CR37","unstructured":"ClinicalTrials.gov (2017) NCT02144012. A study to evaluate the efficacy and safety of trastuzumab emtansine versus the combination of trastuzumab plus docetaxel in patients with HER2-positive breast cancer. Updated. https:\/\/clinicaltrials.gov\/study\/NCT02144012. Accessed 2 Oct 2023"},{"key":"1771_CR38","unstructured":"ClinicalTrials.gov (2016) NCT01419197. A study of trastuzumab emtansine in comparison with treatment of physician\u2019s choice in participants with HER2-positive breast cancer who have received at least two prior regimens of HER2-directed therapy (TH3RESA). Updated. https:\/\/clinicaltrials.gov\/study\/NCT01419197. Accessed 2 Oct 2023"},{"key":"1771_CR39","unstructured":"ClinicalTrials.gov (2023) NCT01853748. T-DM1 vs paclitaxel\/trastuzumab for breast (ATEMPT trial). Updated. https:\/\/clinicaltrials.gov\/study\/NCT01853748. Accessed 2 Oct 2023"},{"key":"1771_CR40","unstructured":"ClinicalTrials.gov (2022) NCT03329690. DS-8201a in human epidermal growth factor receptor 2 (HER2)-expressing gastric cancer [DESTINY-Gastric01]. Updated. https:\/\/clinicaltrials.gov\/study\/NCT03329690. Accessed 2 Oct 2023"},{"key":"1771_CR41","unstructured":"ClinicalTrials.gov (2023) NCT03262935. SYD985 vs. physician\u2019s choice in participants with HER2-positive locally advanced or metastatic breast cancer (TULIP). Updated. https:\/\/clinicaltrials.gov\/study\/NCT03262935. Accessed 2 Oct 2023"},{"key":"1771_CR42","unstructured":"ClinicalTrials.gov (2014) NCT00679341. A study of the efficacy and safety of trastuzumab emtansine (trastuzumab-MCC-DM1) vs. trastuzumab (Herceptin\u00ae) and docetaxel (Taxotere\u00ae) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic disease. Updated. https:\/\/clinicaltrials.gov\/study\/NCT00679341. Accessed 2 Oct 2023"},{"key":"1771_CR43","unstructured":"ClinicalTrials.gov (2017) NCT01120184. A study of trastuzumab emtansine (T-DM1) plus pertuzumab\/pertuzumab placebo versus trastuzumab [Herceptin] plus a taxane in participants with metastatic breast cancer (MARIANNE). Updated. https:\/\/clinicaltrials.gov\/study\/NCT01120184. Accessed 2 Oct 2023"},{"key":"1771_CR44","unstructured":"ClinicalTrials.gov (2022) NCT01966471. A study of trastuzumab emtansine (Kadcyla) plus pertuzumab (Perjeta) following anthracyclines in comparison with trastuzumab (Herceptin) plus pertuzumab and a taxane following anthracyclines as adjuvant therapy in participants with operable HER2-positive primary breast cancer. Updated. https:\/\/clinicaltrials.gov\/study\/NCT01966471. Accessed 2 Oct 2023"},{"key":"1771_CR45","unstructured":"ClinicalTrials.gov (2019) NCT02131064. A study evaluating trastuzumab emtansine plus pertuzumab compared with chemotherapy plus trastuzumab and pertuzumab for participants with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Updated. https:\/\/clinicaltrials.gov\/study\/NCT02131064. Accessed 2 Oct 2023"},{"key":"1771_CR46","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s10147-015-0834-3","volume":"20","author":"M Osawa","year":"2015","unstructured":"Osawa M, Kudoh S, Sakai F et al (2015) Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study. Int J Clin Oncol 20:1063\u20131071. https:\/\/doi.org\/10.1007\/s10147-015-0834-3","journal-title":"Int J Clin Oncol"},{"key":"1771_CR47","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/1060028014566446","volume":"49","author":"T Sakurada","year":"2015","unstructured":"Sakurada T, Kakiuchi S, Tajima S et al (2015) Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. Ann Pharmacother 49:398\u2013404. https:\/\/doi.org\/10.1177\/1060028014566446","journal-title":"Ann Pharmacother"},{"key":"1771_CR48","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/jjco\/hyx010","volume":"47","author":"K Tomii","year":"2017","unstructured":"Tomii K, Kato T, Takahashi M et al (2017) Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma\/non-small cell lung cancer). Jpn J Clin Oncol 47:350\u2013356. https:\/\/doi.org\/10.1093\/jjco\/hyx010","journal-title":"Jpn J Clin Oncol"},{"key":"1771_CR49","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1111\/cas.12550","volume":"105","author":"A Gemma","year":"2014","unstructured":"Gemma A, Kudoh S, Ando M et al (2014) Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci 105:1584\u20131590. https:\/\/doi.org\/10.1111\/cas.12550","journal-title":"Cancer Sci"},{"key":"1771_CR50","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.cllc.2014.06.003","volume":"15","author":"T Johkoh","year":"2014","unstructured":"Johkoh T, Sakai F, Kusumoto M et al (2014) Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib-a cohort study. Clin Lung Cancer 15:448\u2013454. https:\/\/doi.org\/10.1016\/j.cllc.2014.06.003","journal-title":"Clin Lung Cancer"},{"key":"1771_CR51","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cllc.2023.08.014","volume":"24","author":"M Petranovic","year":"2023","unstructured":"Petranovic M, McDermott S, Mercaldo S et al (2023) Impact of baseline interstitial lung abnormalities on pneumonitis risk in patients receiving immune checkpoint inhibitors for non-small-cell lung cancer. Clin Lung Cancer 24:682\u2013688.e5. https:\/\/doi.org\/10.1016\/j.cllc.2023.08.014","journal-title":"Clin Lung Cancer"},{"key":"1771_CR52","unstructured":"Canadian Society of Thoracic Radiology (CSTR) (2020) High resolution CT of the chest recommended technique. https:\/\/car.ca\/wp-content\/uploads\/2020\/02\/High-Resolution-CT-of-the-Chest-Recommended-Technique-2020.pdf. Accessed 18 Jul 2023"},{"key":"1771_CR53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2214\/ajr.177.3.1770501","volume":"177","author":"EA Kazerooni","year":"2001","unstructured":"Kazerooni EA (2001) High-resolution CT of the lungs. AJR Am J Roentgenol 177:501\u2013519. https:\/\/doi.org\/10.2214\/ajr.177.3.1770501","journal-title":"Am J Roentgenol"},{"key":"1771_CR54","doi-asserted-by":"publisher","first-page":"e20200096","DOI":"10.36416\/1806-3756\/e20200096","volume":"47","author":"PP Torres","year":"2021","unstructured":"Torres PP, Rabahi MF, Moreira MA et al (2021) Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases. J Bras Pneumol 47:e20200096. https:\/\/doi.org\/10.36416\/1806-3756\/e20200096","journal-title":"J Bras Pneumol"},{"key":"1771_CR55","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2214\/ajr.185.3.01850602","volume":"185","author":"U Studler","year":"2005","unstructured":"Studler U, Gluecker T, Bongartz G et al (2005) Image quality from high-resolution CT of the lung: comparison of axial scans and of sections reconstructed from volumetric data acquired using MDCT. AJR Am J Roentgenol 185:602\u2013607. https:\/\/doi.org\/10.2214\/ajr.185.3.01850602","journal-title":"Am J Roentgenol"},{"key":"1771_CR56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"American Thoracic Society, European Respiratory Society","year":"2002","unstructured":"American Thoracic Society, European Respiratory Society (2002) American Thoracic Society\/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277\u2013304. https:\/\/doi.org\/10.1164\/ajrccm.165.2.ats01","journal-title":"Am J Respir Crit Care Med"},{"key":"1771_CR57","doi-asserted-by":"publisher","unstructured":"Nishino M, Hatabu H, Hodi FS, Ramaiya NH (2017) Drug-related pneumonitis in the era of precision cancer therapy. JCO Precis Oncol 1:PO.17.00026. https:\/\/doi.org\/10.1200\/PO.17.00026","DOI":"10.1200\/PO.17.00026"},{"key":"1771_CR58","unstructured":"Chandra D, Maini R, Hershberger DM (2023) Cryptogenic organizing pneumonia. In: StatPearls. StatPearls Publishing, Treasure Island, FL, USA"},{"key":"1771_CR59","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382:610\u2013621. https:\/\/doi.org\/10.1056\/NEJMoa1914510","journal-title":"N Engl J Med"},{"key":"1771_CR60","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","volume":"20","author":"K Tamura","year":"2019","unstructured":"Tamura K, Tsurutani J, Takahashi S et al (2019) Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol 20:816\u2013826. https:\/\/doi.org\/10.1016\/S1470-2045(19)30097-X","journal-title":"Lancet Oncol"},{"key":"1771_CR61","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00391","volume":"7","author":"M Nishino","year":"2023","unstructured":"Nishino M, Kusumoto M, Bankier AA et al (2023) Trastuzumab deruxtecan\u2012related interstitial lung disease\/pneumonitis: computed tomography imaging patterns to guide diagnosis and management. JCO Precis Oncol 7:e2300391. https:\/\/doi.org\/10.1200\/PO.23.00391","journal-title":"JCO Precis Oncol"},{"key":"1771_CR62","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s10147-023-02414-x","volume":"28","author":"T Baba","year":"2023","unstructured":"Baba T, Kusumoto M, Kato T et al (2023) Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan. Int J Clin Oncol 28:1585\u20131596. https:\/\/doi.org\/10.1007\/s10147-023-02414-x","journal-title":"Int J Clin Oncol"},{"key":"1771_CR63","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","volume":"50","author":"M Delaunay","year":"2017","unstructured":"Delaunay M, Cadranel J, Lusque A et al (2017) Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 50:1700050. https:\/\/doi.org\/10.1183\/13993003.00050-2017","journal-title":"Eur Respir J"},{"key":"1771_CR64","unstructured":"Chandra D, Cherian SV (2023) Hypersensitivity pneumonitis. In: StatPearls. StatPearls Publishing, Treasure Island, FL, USA"},{"key":"1771_CR65","doi-asserted-by":"publisher","first-page":"210169","DOI":"10.1183\/16000617.0169-2021","volume":"31","author":"M Hamblin","year":"2022","unstructured":"Hamblin M, Prosch H, Va\u0161\u00e1kov\u00e1 M (2022) Diagnosis, course and management of hypersensitivity pneumonitis. Eur Respir Rev 31:210169. https:\/\/doi.org\/10.1183\/16000617.0169-2021","journal-title":"Eur Respir Rev"},{"key":"1771_CR66","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1158\/1078-0432.CCR-20-0454","volume":"26","author":"A Terbuch","year":"2020","unstructured":"Terbuch A, Tiu C, Candilejo IM et al (2020) Radiological patterns of drug-induced interstitial lung disease (DILD) in early-phase oncology clinical trials. Clin Cancer Res 26:4805\u20134813. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0454","journal-title":"Clin Cancer Res"},{"key":"1771_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13244-010-0060-5","volume":"2","author":"W De Wever","year":"2011","unstructured":"De Wever W, Meersschaert J, Coolen J et al (2011) The crazy-paving pattern: a radiological-pathological correlation. Insights Imaging 2:117\u2013132. https:\/\/doi.org\/10.1007\/s13244-010-0060-5","journal-title":"Insights Imaging"},{"key":"1771_CR68","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1055\/s-0032-1325158","volume":"33","author":"S Mukhopadhyay","year":"2012","unstructured":"Mukhopadhyay S, Parambil JG (2012) Acute interstitial pneumonia (AIP): relationship to Hamman-Rich syndrome, diffuse alveolar damage (DAD), and acute respiratory distress syndrome (ARDS). Semin Respir Crit Care Med 33:476\u2013485. https:\/\/doi.org\/10.1055\/s-0032-1325158","journal-title":"Semin Respir Crit Care Med"},{"key":"1771_CR69","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","volume":"161","author":"American Thoracic Society, European Respiratory Society","year":"2000","unstructured":"American Thoracic Society, European Respiratory Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161:646\u2013664. https:\/\/doi.org\/10.1164\/ajrccm.161.2.ats3-00","journal-title":"Am J Respir Crit Care Med"},{"key":"1771_CR70","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2013-203618","volume":"68","author":"IA Du Rand","year":"2013","unstructured":"Du Rand IA, Blaikley J, Booton R et al (2013) British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax 68:i1\u2013i44. https:\/\/doi.org\/10.1136\/thoraxjnl-2013-203618","journal-title":"Thorax"},{"key":"1771_CR71","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00432-022-03932-3","volume":"148","author":"S Kaku","year":"2022","unstructured":"Kaku S, Horinouchi H, Watanabe H et al (2022) Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world. J Cancer Res Clin Oncol 148:1737\u20131746. https:\/\/doi.org\/10.1007\/s00432-022-03932-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"1771_CR72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/JIPO.JIPO_9_18","volume":"1","author":"A Jain","year":"2018","unstructured":"Jain A, Shannon VR, Sheshadri A (2018) Pneumonitis after precision oncology therapies: a concise review. J Immunother Precis Oncol 1:26\u201337. https:\/\/doi.org\/10.4103\/JIPO.JIPO_9_18","journal-title":"J Immunother Precis Oncol"},{"key":"1771_CR73","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","volume":"13","author":"I Gkiozos","year":"2018","unstructured":"Gkiozos I, Kopitopoulou A, Kalkanis A et al (2018) Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol 13:1076\u20131082. https:\/\/doi.org\/10.1016\/j.jtho.2018.04.031","journal-title":"J Thorac Oncol"},{"key":"1771_CR74","unstructured":"Bokhari SR, Zulfiqar H, Mansur A (2023) Sarcoidosis. In: StatPearls. StatPearls Publishing, Treasure Island, FL, USA"},{"key":"1771_CR75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/2010105818766363","volume":"28","author":"QL Tan","year":"2019","unstructured":"Tan QL, Leow LC, Mohideen SM, Sewa DW (2019) Sarcoid-like reaction associated with lung adenocarcinoma: a case report. Proc Singap Heal 28:68\u201370. https:\/\/doi.org\/10.1177\/2010105818766363","journal-title":"Proc Singap Heal"},{"key":"1771_CR76","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.3390\/cancers14194642","volume":"14","author":"P-R Jan","year":"2022","unstructured":"Jan P-R, Chang JW-C, Wu C-E (2022) Radiation recall pneumonitis: a rare syndrome that should be recognized. Cancers Basel 14:4642. https:\/\/doi.org\/10.3390\/cancers14194642","journal-title":"Cancers Basel"},{"key":"1771_CR77","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1148\/rg.2019190036","volume":"39","author":"KR Kalisz","year":"2019","unstructured":"Kalisz KR, Ramaiya NH, Laukamp KR, Gupta A (2019) Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management. Radiographics 39:1923\u20131937. https:\/\/doi.org\/10.1148\/rg.2019190036","journal-title":"Radiographics"},{"key":"1771_CR78","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jcma.2016.01.008","volume":"79","author":"C-L Chiang","year":"2016","unstructured":"Chiang C-L, Chen Y-W, Wu M-H et al (2016) Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced non-small cell lung cancer. J Chin Med Assoc 79:248\u2013255. https:\/\/doi.org\/10.1016\/j.jcma.2016.01.008","journal-title":"J Chin Med Assoc"},{"key":"1771_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.823767","volume":"13","author":"M Wang","year":"2022","unstructured":"Wang M, Xu S, Zhu H (2022) Radiation recall pneumonitis induced by sintilimab: a case report and literature review. Front Immunol 13:823767. https:\/\/doi.org\/10.3389\/fimmu.2022.823767","journal-title":"Front Immunol"},{"key":"1771_CR80","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/annonc\/mdx115","volume":"28","author":"R Shibaki","year":"2017","unstructured":"Shibaki R, Akamatsu H, Fujimoto M et al (2017) Nivolumab induced radiation recall pneumonitis after two years of radiotherapy. Ann Oncol 28:1404\u20131405. https:\/\/doi.org\/10.1093\/annonc\/mdx115","journal-title":"Ann Oncol"},{"key":"1771_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-6-24","volume":"6","author":"X Ding","year":"2011","unstructured":"Ding X, Ji W, Li J et al (2011) Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer. Radiat Oncol 6:24. https:\/\/doi.org\/10.1186\/1748-717X-6-24","journal-title":"Radiat Oncol"},{"key":"1771_CR82","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.rmcr.2013.07.003","volume":"10","author":"T Suzuki","year":"2013","unstructured":"Suzuki T, Tada Y, Tsushima K et al (2013) Pneumocystis pneumonia in everolimus therapy: an indistinguishable case from drug induced interstitial lung disease. Respir Med Case Rep 10:27\u201330. https:\/\/doi.org\/10.1016\/j.rmcr.2013.07.003","journal-title":"Respir Med Case Rep"},{"key":"1771_CR83","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/diagnostics11081306","volume":"11","author":"F Pirrotta","year":"2021","unstructured":"Pirrotta F, Mazza B, Gennari L, Palazzuoli A (2021) Pulmonary congestion assessment in heart failure: traditional and new tools. Diagn Basel 11:1306. https:\/\/doi.org\/10.3390\/diagnostics11081306","journal-title":"Diagn Basel"},{"key":"1771_CR84","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.chest.2017.03.033","volume":"152","author":"N Azadeh","year":"2017","unstructured":"Azadeh N, Limper AH, Carmona EM, Ryu JH (2017) The role of infection in interstitial lung diseases: a review. Chest 152:842\u2013852. https:\/\/doi.org\/10.1016\/j.chest.2017.03.033","journal-title":"Chest"},{"key":"1771_CR85","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1136\/thx.2008.110445","volume":"64","author":"AG Richter","year":"2009","unstructured":"Richter AG, Stockley RA, Harper L, Thickett DR (2009) Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis. Thorax 64:692\u2013697. https:\/\/doi.org\/10.1136\/thx.2008.110445","journal-title":"Thorax"},{"key":"1771_CR86","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00134-022-06877-w","volume":"48","author":"P Mehta","year":"2022","unstructured":"Mehta P, Rosas IO, Singer M (2022) Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity. Intensive Care Med 48:1803\u20131806. https:\/\/doi.org\/10.1007\/s00134-022-06877-w","journal-title":"Intensive Care Med"},{"key":"1771_CR87","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.resinv.2013.07.005","volume":"52","author":"A Ushiki","year":"2014","unstructured":"Ushiki A, Yamazaki Y, Hama M et al (2014) Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia. Respir Investig 52:65\u201370. https:\/\/doi.org\/10.1016\/j.resinv.2013.07.005","journal-title":"Respir Investig"},{"key":"1771_CR88","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 198:e44\u2013e68. https:\/\/doi.org\/10.1164\/rccm.201807-1255ST","journal-title":"Am J Respir Crit Care Med"},{"key":"1771_CR89","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1159\/000525800","volume":"15","author":"T Imakita","year":"2022","unstructured":"Imakita T, Fujita K, Kanai O, Mio T (2022) Pulmonary lymphangitis carcinomatosa mimicking immunotherapy-related interstitial pneumonitis: a case report. Case Rep Oncol 15:732\u2013737. https:\/\/doi.org\/10.1159\/000525800","journal-title":"Case Rep Oncol"},{"key":"1771_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-5-638","volume":"5","author":"K Moubax","year":"2012","unstructured":"Moubax K, Wuyts W, Vandecaveye V, Prenen H (2012) Pulmonary lymphangitic carcinomatosis as a primary manifestation of gastric carcinoma in a young adult: a case report and review of the literature. BMC Res Notes 5:638. https:\/\/doi.org\/10.1186\/1756-0500-5-638","journal-title":"BMC Res Notes"},{"key":"1771_CR91","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1136\/thx.2008.101691","volume":"63","author":"B Bradley","year":"2008","unstructured":"Bradley B, Branley HM, Egan JJ et al (2008) Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63:v1\u2013v58. https:\/\/doi.org\/10.1136\/thx.2008.101691","journal-title":"Thorax"},{"key":"1771_CR92","doi-asserted-by":"publisher","first-page":"w14318","DOI":"10.4414\/smw.2016.14318","volume":"146","author":"SA Guler","year":"2016","unstructured":"Guler SA, Berezowska SA, Christe A et al (2016) Multidisciplinary discussion for diagnosis of interstitial lung disease in real life. Swiss Med Wkly 146:w14318. https:\/\/doi.org\/10.4414\/smw.2016.14318","journal-title":"Swiss Med Wkly"},{"key":"1771_CR93","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","volume":"6","author":"DA Lynch","year":"2018","unstructured":"Lynch DA, Sverzellati N, Travis WD et al (2018) Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 6:138\u2013153. https:\/\/doi.org\/10.1016\/S2213-2600(17)30433-2","journal-title":"Lancet Respir Med"},{"key":"1771_CR94","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1469-0691.2005.01337.x","volume":"12","author":"S Vidal","year":"2006","unstructured":"Vidal S, de la Horra C, Mart\u00edn J et al (2006) Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clin Microbiol Infect 12:231\u2013235. https:\/\/doi.org\/10.1111\/j.1469-0691.2005.01337.x","journal-title":"Clin Microbiol Infect"},{"key":"1771_CR95","unstructured":"Truong J, Ashurst JV (2023) Pneumocystis jirovecii pneumonia. In: StatPearls. StatPearls Publishing, Treasure Island, FL, USA"},{"key":"1771_CR96","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3390\/diagnostics12122925","volume":"12","author":"Y Sun","year":"2022","unstructured":"Sun Y, Shao C, Huang H et al (2022) Prognostic analysis of Pneumocystis jirovecii pneumonia in interstitial lung disease patients: a retrospective clinical study. Diagn Basel 12:2925. https:\/\/doi.org\/10.3390\/diagnostics12122925","journal-title":"Diagn Basel"},{"key":"1771_CR97","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/jjco\/hyt019","volume":"43","author":"Y Saito","year":"2013","unstructured":"Saito Y, Nagayama M, Miura Y et al (2013) A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma. Jpn J Clin Oncol 43:559\u2013562. https:\/\/doi.org\/10.1093\/jjco\/hyt019","journal-title":"Jpn J Clin Oncol"},{"key":"1771_CR98","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13244-012-0207-7","volume":"4","author":"A Oikonomou","year":"2012","unstructured":"Oikonomou A, Prassopoulos P (2012) Mimics in chest disease: interstitial opacities. Insights Imaging 4:9\u201327. https:\/\/doi.org\/10.1007\/s13244-012-0207-7","journal-title":"Insights Imaging"},{"key":"1771_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H et al (2022) Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 7:100554. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100554","journal-title":"ESMO Open"},{"key":"1771_CR100","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/RLI.0000000000000974","volume":"58","author":"E Dack","year":"2023","unstructured":"Dack E, Christe A, Fontanellaz M et al (2023) Artificial intelligence and interstitial lung disease: diagnosis and prognosis. Invest Radiol 58:602\u2013609. https:\/\/doi.org\/10.1097\/RLI.0000000000000974","journal-title":"Invest Radiol"},{"key":"1771_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102043","volume":"8","author":"D Wekking","year":"2023","unstructured":"Wekking D, Porcu M, Pellegrino B et al (2023) Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients. ESMO Open 8:102043. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102043","journal-title":"ESMO Open"},{"key":"1771_CR102","doi-asserted-by":"publisher","first-page":"2002042","DOI":"10.1183\/13993003.02042-2020","volume":"57","author":"CC Moor","year":"2021","unstructured":"Moor CC, Oppenheimer JC, Nakshbandi G et al (2021) Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. Eur Respir J 57:2002042. https:\/\/doi.org\/10.1183\/13993003.02042-2020","journal-title":"Eur Respir J"},{"key":"1771_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99682-2","volume":"11","author":"S Shahrestani","year":"2021","unstructured":"Shahrestani S, Chou T-C, Shang K-M et al (2021) A wearable eddy current based pulmonary function sensor for continuous non-contact point-of-care monitoring during the COVID-19 pandemic. Sci Rep 11:20144. https:\/\/doi.org\/10.1038\/s41598-021-99682-2","journal-title":"Sci Rep"},{"key":"1771_CR104","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1200\/OP.23.00097","volume":"19","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Tolaney SM (2023) Detecting and managing T-DXd-related interstitial lung disease: the five \u201cS\u201d rules. JCO Oncol Pr 19:526\u2013527. https:\/\/doi.org\/10.1200\/OP.23.00097","journal-title":"JCO Oncol Pr"},{"key":"1771_CR105","unstructured":"AstraZeneca, Daiichi Sankyo (2023) Trastuzumab deruxtecan (T-DXd) investigator\u2019s brochure"},{"key":"1771_CR106","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1200\/JCO.2013.54.4999","volume":"32","author":"V Di\u00e9ras","year":"2014","unstructured":"Di\u00e9ras V, Harbeck N, Budd GT et al (2014) Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol 32:2750\u20132757. https:\/\/doi.org\/10.1200\/JCO.2013.54.4999","journal-title":"J Clin Oncol"},{"key":"1771_CR107","doi-asserted-by":"publisher","first-page":"327","DOI":"10.5732\/cjc.010.10507","volume":"30","author":"B-H Xu","year":"2011","unstructured":"Xu B-H, Jiang Z-F, Chua D et al (2011) Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer 30:327\u2013335. https:\/\/doi.org\/10.5732\/cjc.010.10507","journal-title":"Chin J Cancer"},{"key":"1771_CR108","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/annonc\/mdp373","volume":"21","author":"G Capri","year":"2010","unstructured":"Capri G, Chang J, Chen S-C et al (2010) An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 21:474\u2013480. https:\/\/doi.org\/10.1093\/annonc\/mdp373","journal-title":"Ann Oncol"},{"key":"1771_CR109","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/annonc\/mdn759","volume":"20","author":"KL Blackwell","year":"2009","unstructured":"Blackwell KL, Pegram MD, Tan-Chiu E et al (2009) Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 20:1026\u20131031. https:\/\/doi.org\/10.1093\/annonc\/mdn759","journal-title":"Ann Oncol"},{"key":"1771_CR110","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","volume":"21","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Wardley AM, Zambelli S et al (2020) Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol 21:763\u2013775. https:\/\/doi.org\/10.1016\/S1470-2045(20)30112-1","journal-title":"Lancet Oncol"},{"key":"1771_CR111","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SR Johnston","year":"2020","unstructured":"Johnston SR, Harbeck N, Hegg R et al (2020) Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 38:3987\u20133998. https:\/\/doi.org\/10.1200\/JCO.20.02514","journal-title":"J Clin Oncol"},{"key":"1771_CR112","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","volume":"22","author":"EL Mayer","year":"2021","unstructured":"Mayer EL, Dueck AC, Martin M et al (2021) Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 22:212\u2013222. https:\/\/doi.org\/10.1016\/S1470-2045(20)30642-2","journal-title":"Lancet Oncol"},{"key":"1771_CR113","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.1002\/onco.13684","volume":"26","author":"RS Finn","year":"2021","unstructured":"Finn RS, Rugo HS, Gelmon KA et al (2021) Long\u2010term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor\u2010positive\/human epidermal growth factor receptor 2\u2010negative advanced breast cancer: updated analysis with up to 5\u2009years of follow\u2010up. Oncologist 26:e749\u2013e755. https:\/\/doi.org\/10.1002\/onco.13684","journal-title":"Oncologist"},{"key":"1771_CR114","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S et al (2020) Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 382:514\u2013524. https:\/\/doi.org\/10.1056\/NEJMoa1911149","journal-title":"N Engl J Med"},{"key":"1771_CR115","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"S-A Im","year":"2019","unstructured":"Im S-A, Lu Y-S, Bardia A et al (2019) Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381:307\u2013316. https:\/\/doi.org\/10.1056\/NEJMoa1903765","journal-title":"N Engl J Med"},{"key":"1771_CR116","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"1771_CR117","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","volume":"17","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J et al (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol 17:883\u2013895. https:\/\/doi.org\/10.1016\/S1470-2045(16)30098-5","journal-title":"Lancet Oncol"},{"key":"1771_CR118","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Chesney J, Pavlick AC et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17:1558\u20131568. https:\/\/doi.org\/10.1016\/S1470-2045(16)30366-7","journal-title":"Lancet Oncol"},{"key":"1771_CR119","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532. https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"1771_CR120","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","volume":"9","author":"MA Socinski","year":"2023","unstructured":"Socinski MA, Jotte RM, Cappuzzo F et al (2023) Association of immune-related adverse events with efficacy of atezolizumab in patients with non\u2013small cell lung cancer. JAMA Oncol 9:527\u2013535. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7711","journal-title":"JAMA Oncol"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-024-01771-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-024-01771-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-024-01771-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T16:06:38Z","timestamp":1722528398000},"score":1,"resource":{"primary":{"URL":"https:\/\/insightsimaging.springeropen.com\/articles\/10.1186\/s13244-024-01771-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1771"],"URL":"https:\/\/doi.org\/10.1186\/s13244-024-01771-z","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"University Hospital LMU Munich guidelines do not require individual consent for publication of images, as long as they are anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.D.: Speaker and\/or consulting fees from AstraZeneca, Boehringer Ingelheim and Daiichi Sankyo, and participation in the ILD advisory committee for the DESTINY-Breast12 study for AstraZeneca and Daiichi Sankyo. N.K.: Speaker and\/or consulting fees from AstraZeneca and Daiichi Sankyo, and participation in the ILD advisory committee for the DESTINY-Breast12 study for AstraZeneca and Daiichi Sankyo. P.T.: Research funds (to institution) and support attending meetings from AstraZeneca, and speaker and\/or consulting fees from AstraZeneca, Daiichi Sankyo, Eli Lilly and Company, Genentech, Gilead, Novartis, and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}